Scott Stryker
Amgen
31 Papers
95 Citations
Scott Stryker is an academic researcher from Amgen. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 10, co-authored 26 publications.
Chat about Author
Papers
Estimated number of prevalent cases of metastatic bone disease in the US adult population.
Shuling Li,Yi Peng,Eric D. Weinhandl,Anne H. Blaes,Karynsa Cetin,Victoria M. Chia,Scott Stryker,Joseph J Pinzone,John F. Acquavella,Thomas J. Arneson +9 more
TL;DR: The findings suggest that approximately 280,000 US adults were living with metastatic bone disease on December 31, 2008, which likely underestimates the true frequency; not all cases of metastaticBone disease are diagnosed, and some diagnosed cases might lack documentation in claims data.
Population-based study of giant cell tumor of bone in Sweden (1983-2011)
Justyna Amelio,Julia Rockberg,Rohini K. Hernandez,Patrik Sobocki,Scott Stryker,Bruce A. Bach,Jacob Engellau,Alexander Liede +7 more
TL;DR: In the modern population-based series primary malignant cases were uncommon, peak incidence 20-39 years with slight predominance in women, and recurrence rates remain significant with overall 39% occurring in benign GCTB, and 75% in malignant form.
59
Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study
Mette Nørgaard,Karynsa Cetin,Merete Lund Maegbaek,Nickolaj R. Kristensen,Waleed Ghanima,Shahram Bahmanyar,Scott Stryker,Christian Fynbo Christiansen +7 more
TL;DR: Howell-Jolly bodylike inclusions in immunocompromised patients with antiviral treatment and first description in leucocytes other than neutrophils are described.
57
Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies
TL;DR: The risk of ATE and VTE among patients with ITP, based on evidence from three large, population-based observational studies, should be considered when evaluating the risk of thromboembolism attributed to ITP treatments, such as TPOr agonists.
47
Summary of worldwide pediatric malignancies reported after exposure to etanercept
Peter McCroskery,Carol A. Wallace,Daniel J. Lovell,Scott Stryker,Nataliya Chernyukhin,Consuelo Blosch,Debra Zack +6 more
TL;DR: The data suggest that there does not appear to be an increased risk of malignancy overall with the use of etanercept, and the expected rate of lymphoma in biologic naïve JIA patients is currently unknown.